Impact of conjugate 7-valent vaccination in Belgium: Addressing methodological challenges
Impact of conjugate 7-valent vaccination in Belgium: Addressing methodological challenges
复制标题
DOI：
10.1016/j.vaccine.2011.02.016
复制
发表时间：
2011-04-05
期刊：
影响因子：
5.5
通讯作者：
Sabbe, Martine
中科院分区：
文献类型：
--
作者：
Hanquet, Germaine;Lernout, Tinne;Sabbe, Martine
在比利时，7价肺炎球菌结合疫苗（PCV7）于2007年被纳入国家计划。通过比较国家监测的疫苗接种前和疫苗接种后发病率，评估了PCV7疫苗接种对儿科侵袭性疾病的早期影响。在 2 岁以下的儿童中，疫苗血清型发病率下降了 96%，但非疫苗血清型发病率增加了 2-3 倍。总体侵袭性疾病减少了 23-46%，具体取决于对漏报和疫苗接种前趋势的调整。非疫苗 1 型和 19A 型在使用 PCV7 之前有所增加，表明有其他因素的影响。比较疫苗接种前和疫苗后数据对 PCV7 影响的估计应根据疫苗前的趋势进行调整，血清型动态需要进一步探索。 (C) 2011 Elsevier Ltd. 保留所有权利。
In Belgium, the 7-valent pneumococcal conjugate vaccine (PCV7) was introduced into the national schedule in 2007. The early impact of PCV7 vaccination on paediatric invasive disease was estimated by comparing pre- and post-vaccination incidence from national surveillance. In children < 2 year-olds, vaccine-serotype incidence declined by 96% but non-vaccine-types increased 2-3-fold. Overall invasive disease decreased by 23-46%, depending on adjustment for under-reporting and pre-vaccine trends. Non-vaccine-types 1 and 19A had increased before PCV7 use, suggesting the contribution of other factors. Estimation of PCV7 impact comparing pre- and post-vaccination data should adjust for pre-vaccine trends, and serotype dynamics need further exploration. (C) 2011 Elsevier Ltd. All rights reserved.